Back to Search Start Over

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Authors :
Eslam, Mohammed
Newsome, Philip N.
Sarin, Shiv
Anstee, Quentin M.
Targher, Giovanni
Romero-Gómez, Manuel
Zelber-Sagi, Shira
Wai‐Sun Wong, Vincent
Dufour, Jean-François
Schattenberg, Jörn M.
Kawaguchi, Takumi
Arrese, Marco
Valenti, Luca
Shiha, Gamal
Tiribelli, Claudio
Yki-Järvinen, Hannele
Fan, Jian-Gao
Grønbæk, Henning
Yilmaz, Yusuf
Cortez-Pinto, Helena
Oliveira, Claudia P.
Bedossa, Pierre
Adams, Leon A.
Zheng, Ming-Hua
Fouad, Yasser
Chan, Wah-Kheong
Méndez-Sánchez, Nahum
Ahn, Sang Hoon
Castera, Laurent
Bugianesi, Elisabetta
Ratziu, Vlad
George, Jacob
Sydney Medical Foundation
University of Sydney
National Health and Medical Research Council (Australia)
National Institute for Health Research (UK)
Birmingham Biomedical Research Centre
University of Birmingham
National Health Service (UK)
Source :
Digital.CSIC. Repositorio Institucional del CSIC, instname
Publication Year :
2020
Publisher :
Elsevier, 2020.

Abstract

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward. ME and JG are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant ( APP1053206 , APP1149976 ) and Project grants ( APP1107178 and APP1108422 ). PNN is supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham .

Details

Database :
OpenAIRE
Journal :
Digital.CSIC. Repositorio Institucional del CSIC, instname
Accession number :
edsair.RECOLECTA.....7a755a300cf8356792f29e51a6097bb2